{"id":48694,"date":"2022-09-22T14:01:54","date_gmt":"2022-09-22T12:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/"},"modified":"2022-09-22T14:01:54","modified_gmt":"2022-09-22T12:01:54","slug":"imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/","title":{"rendered":"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference"},"content":{"rendered":"
\n

PHILADELPHIA–(BUSINESS WIRE)–Imvax, Inc.<\/a>, a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation at the 2022 International Cancer Immunotherapy Conference (CICON) in New York City, NY, from September 28 \u2013 October 1, 2022.\n<\/p>\n

<\/a><\/p>\n

\nAt the meeting, Imvax will present preclinical data that further elucidate the foundational anti-tumor immunological mechanisms of its platform and provide additional evidence of activity in an endometrial cancer model.\n<\/p>\n

\nThe details of the poster presentation are:\n<\/p>\n

\nTitle:<\/b> Autologous tumor cell immunotherapeutic platform, with evidence of clinical activity in glioblastoma, induces in vitro immune responses in both glioblastoma and endometrial cancer
\n
<\/i>Abstract Submission Number:<\/b> 0688_0974_000292
\n
Timing:<\/b> Thursday, September 29th<\/sup>, 12:00 p.m. \u2013 2:00 p.m. EST
\n
Presenter:<\/b> Dr. Christopher Uhl\n<\/p>\n

\nAbout Imvax, Inc.
\n
<\/b>Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax\u2019s portfolio includes several programs designed to stimulate a patient\u2019s immune system against the entire antigen signature of their tumor. Imvax\u2019s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax is headquartered in Philadelphia, PA. For additional information, please visit www.imvax.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:
\n
<\/b>Thomas Stephenson
\n
Ten Bridge Communications
\n
thomas@tenbridgecommunications.com<\/a>
(857) 244-0246\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA–(BUSINESS WIRE)–Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation at the 2022 International Cancer Immunotherapy Conference (CICON) in New York City, NY, from September 28 \u2013 October 1, 2022. At the meeting, Imvax will present preclinical data that further elucidate the foundational anti-tumor immunological mechanisms of its … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48694","6":"format-standard","7":"category-industry"},"yoast_head":"\nImvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA–(BUSINESS WIRE)–Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation at the 2022 International Cancer Immunotherapy Conference (CICON) in New York City, NY, from September 28 \u2013 October 1, 2022. At the meeting, Imvax will present preclinical data that further elucidate the foundational anti-tumor immunological mechanisms of its ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T12:01:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220920006153\/en\/1577999\/21\/Imvax-Logo-CMYK_Midnight.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference\",\"datePublished\":\"2022-09-22T12:01:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/\"},\"wordCount\":211,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220920006153\\\/en\\\/1577999\\\/21\\\/Imvax-Logo-CMYK_Midnight.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/\",\"name\":\"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220920006153\\\/en\\\/1577999\\\/21\\\/Imvax-Logo-CMYK_Midnight.jpg\",\"datePublished\":\"2022-09-22T12:01:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220920006153\\\/en\\\/1577999\\\/21\\\/Imvax-Logo-CMYK_Midnight.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220920006153\\\/en\\\/1577999\\\/21\\\/Imvax-Logo-CMYK_Midnight.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/","og_locale":"en_US","og_type":"article","og_title":"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference - Pharma Trend","og_description":"PHILADELPHIA–(BUSINESS WIRE)–Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation at the 2022 International Cancer Immunotherapy Conference (CICON) in New York City, NY, from September 28 \u2013 October 1, 2022. At the meeting, Imvax will present preclinical data that further elucidate the foundational anti-tumor immunological mechanisms of its ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-22T12:01:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220920006153\/en\/1577999\/21\/Imvax-Logo-CMYK_Midnight.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference","datePublished":"2022-09-22T12:01:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/"},"wordCount":211,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220920006153\/en\/1577999\/21\/Imvax-Logo-CMYK_Midnight.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/","url":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/","name":"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220920006153\/en\/1577999\/21\/Imvax-Logo-CMYK_Midnight.jpg","datePublished":"2022-09-22T12:01:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220920006153\/en\/1577999\/21\/Imvax-Logo-CMYK_Midnight.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220920006153\/en\/1577999\/21\/Imvax-Logo-CMYK_Midnight.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/imvax-to-present-new-data-on-tumor-derived-immunotherapy-platform-at-2022-international-cancer-immunotherapy-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48694"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48694\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}